Editas Medicine

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Retrieved on: 
Wednesday, February 28, 2024

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates.
  • In 2023, Editas Medicine strengthened and focused its discovery organization to build an in vivo gene editing pipeline.
  • Editas Medicine plans to participate in the following investor events:
    The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m.
  • ET to provide and discuss a corporate update and financial results for the fourth quarter and full year of 2023.

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

Retrieved on: 
Wednesday, February 21, 2024

ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update.

Key Points: 
  • ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update.
  • To access the conference call:
    U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins.
  • Participants should ask to be connected to the Editas Medicine Earnings Conference Call.
  • The conference call will also be webcast and can be accessed from the “Investors” section of the Editas Medicine website at https://www.editasmedicine.com .

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024

CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, will discuss the Company’s 2024 strategic priorities and anticipated milestones at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, at 4:30 p.m. PST.

Key Points: 
  • “2023 was a pivotal year for Editas as we launched and executed our focused strategy, strengthened our leadership team, and hit multiple clinical milestones to drive Editas’ transformation towards a commercial-stage company.
  • We expect 2024 to be even more eventful as we continue to develop our potentially transformative experimental medicines,” said Dr. O’Neill.
  • To be a part of this chapter of Editas’ journey is invigorating, and I look forward to what’s next.”
    Dr. O’Neill will discuss the Company’s strategic priorities and 2024 anticipated key milestones for its gene editing medicines and platform technology at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 4:30 p.m. PT / 7:30 p.m.
  • A live webcast of the presentation will be available on the “Investors” section of the Editas Medicine website at www.editasmedicine.com .

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30 p.m. PT / 7:30 p.m.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30 p.m. PT / 7:30 p.m.
  • ET in San Francisco, CA.
  • A live webcast of the presentation will be available on the “Investors” section of the Editas Medicine website at www.editasmedicine.com .
  • An archived replay will be available on the website for approximately 30 days following the presentation.

Xtalks Releases Life Science Trends to Look Out For In 2024

Retrieved on: 
Tuesday, January 2, 2024

TORONTO, Jan. 2, 2024 /PRNewswire-PRWeb/ -- Xtalks, a leading provider of educational webinars to the global life science, healthcare, medical device and food communities, released a list of life science trends and predictions for 2024. Xtalks' Senior Life Science Journalist Ayesha Rashid outlines some of the major trends in the life sciences that are expected in 2024, speaking to some industry experts and innovators for their insights and predictions.

Key Points: 
  • TORONTO, Jan. 2, 2024 /PRNewswire-PRWeb/ -- Xtalks, a leading provider of educational webinars to the global life science, healthcare, medical device and food communities, released a list of life science trends and predictions for 2024.
  • Xtalks' Senior Life Science Journalist Ayesha Rashid outlines some of the major trends in the life sciences that are expected in 2024, speaking to some industry experts and innovators for their insights and predictions.
  • Stay tuned for all of the latest trends and news in the life sciences in 2024 through our articles, video content, webinars and the Xtalks Life Science Podcast.
  • To learn more about Xtalks' Life Science Trends for 2024, check out Life Science Trends to Look Out for in 2024 .

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Retrieved on: 
Wednesday, December 13, 2023

CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company and Vertex Pharmaceuticals entered into a license agreement. Under terms of the agreement, Vertex will obtain a non-exclusive license for Editas Medicine’s Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, including CASGEVY™ (exagamglogene autotemcel). This agreement extends Editas Medicine’s cash runway into 2026.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company and Vertex Pharmaceuticals entered into a license agreement.
  • Under terms of the agreement, Vertex will obtain a non-exclusive license for Editas Medicine’s Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, including CASGEVY™ (exagamglogene autotemcel).
  • Editas Medicine is the exclusive licensee of certain CRISPR patent estates for making human medicines.
  • The Cas9 gene editing technology provides access to a broad range of genetic mutations, delivering a precise and targeted approach to gene editing medicines.

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

Retrieved on: 
Monday, December 11, 2023

The total dataset of 17 treated patients includes 12 additional patients since the data presentation at the European Hematology Association (EHA) Annual Congress and in a Company-sponsored webinar this past June.

Key Points: 
  • The total dataset of 17 treated patients includes 12 additional patients since the data presentation at the European Hematology Association (EHA) Annual Congress and in a Company-sponsored webinar this past June.
  • Editas Medicine will present the RUBY and EdiTHAL trial data today at 1 p.m.
  • The data will also be presented in a poster presentation at the American Society of Hematology (ASH) Annual Meeting in San Diego, CA, at 6:00 p.m. PT (9:00 p.m.
  • Presenting Author: Rabi Hanna, M.D., Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Children’s, Cleveland, OH, United States

Sensorium Therapeutics Announces Appointment of Veteran Biotech Executive Alexandra Glucksmann, Ph.D., as CEO as the Company Progresses Toward the Clinic

Retrieved on: 
Monday, December 4, 2023

BOSTON, Dec. 4, 2023 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company leveraging machine learning, medicinal chemistry and neuroscience to develop nature-inspired psychoactive medicines for mental health, today announced its incoming Chief Executive Officer. Sensorium welcomed Alexandra (Sandra) Glucksmann, Ph.D., as CEO and President, as former CEO and Co-founder, Dick Simon, transitions to an advisory role while continuing to serve on the Board of Directors.

Key Points: 
  • Sensorium welcomed Alexandra (Sandra) Glucksmann, Ph.D., as CEO and President, as former CEO and Co-founder, Dick Simon, transitions to an advisory role while continuing to serve on the Board of Directors.
  • We're thrilled with the caliber of leadership Sandra brings to shepherd Sensorium towards the clinic and beyond."
  • Alexandra holds a Ph.D. with honors in molecular genetics and cell biology from the University of Chicago.
  • The award underscores the company's flexible, platform-based approach and commitment to applying its next-gen platform to bring forward modern medicines across mental health and CNS.

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, November 7, 2023

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update.
  • Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $27.6 million, compared to $16.9 million for the third quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $7.7 million, compared to $7.2 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $33.2 million, compared to $23.8 million for the third quarter of 2022.

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

Retrieved on: 
Friday, November 3, 2023

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates.
  • Cash, cash equivalents, and marketable securities as of September 30, 2023, were $446.4 million compared to $480.0 million as of June 30, 2023.
  • The increase is primarily related to an upfront payment for the non-exclusive Cas9 license to Vor Bio in the third quarter of 2023.
  • Editas Medicine plans to participate in the following scientific and medical conference:
    Editas Medicine plans to participate in the following investor events: